ArticleJournal of orthopaedic surgery and research2026
Freezing nitrogen ethanol composite in treating giant cell tumor of bone: a clinical series of 32 patients.
Article in Journal of orthopaedic surgery and research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGiant cell tumor of bone (GCTB) is a benign yet locally aggressive tumor that often affects young adults around the knee. Intralesional curettage with adjuvants reduces recurrence but complications remain. Freezing nitrogen ethanol composite (FNEC), a semi-solid cryogen, has emerged as a novel adjunct with promising early results. This study evaluated the mid- to long-term outcomes of FNEC following curettage for GCTB.
methodsA retrospective review of consecutive GCTB patients underwent intralesional curettage and FNEC cryotherapy between 2017 and 2022. A standardized three-phase protocol (pre-cooling, freezing, thawing) was applied after intralesional curettage and before bone grafting or substitute filling, with fixation as required. Demographics, tumor characteristics, and disease status at presentation (primary vs. recurrent), oncological outcome, complications, and functional outcome were recorded.
resultsThe cohort included 17 men and 15 women, mean age 34.8 years. Eighteen lesions (56.3%) were around the knee, the rest in the distal radius, proximal humerus, proximal femur, talus, and metatarsus. Four recurrences (12.5%) occurred, yielding 2- and 5-year recurrence-free-survival of 93.8% and 90.6%. Patients with primary lesion had superior recurrence-free survival compared with recurrent lesion (95.0% and 95.0% vs. 91.7% and 83.3% at 2 and 5 years). No recurrence was observed in primary knee lesions. Complications included one wound dehiscence and one case of subcutaneous irritation. No fractures or structural collapse was noted. The mean MSTS score was 93.2%.
conclusionFNEC is a safe and effective adjuvant for curettage in GCTB, achieving excellent local control and functional outcomes with minimal complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.